Clinical trials

  • OCRELIZUMAB for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Secondary progressive multiple sclerosis (active)
  • METHYLPREDNISOLONE for Fulminant myocarditis
  • Izaflortaucipir (18F) for Down syndrome|Alzheimer's disease
  • USTEKINUMAB for Crohn's disease
  • GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
  • Darovasertib for Metastatic uveal melanoma (HLA-A2 negative)
  • Abemaciclib for Stage IV lung cancer | Breast cancer
  • CONCIZUMAB for Haemophilia A with inhibitors | Haemophilia B with inhibitors
  • CENOBAMATE for Partial-onset (focal) seizures
  • BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
  • AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
  • Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)